| 摘要 |
The present invention provides Fc fusion proteins with reduced or no Fc-mediated effector activities for use in therapy. Fc fusions proteins produced in accordance with the present invention are easy to purify, have longer circulating half lives compared to proteins without the Fc portion, and yet have minimal or no Fc-mediated effector activities.
|
